IKT
NASDAQInhibikase Therapeutics Inc.
Price$1.62-0.28 (-14.74%)
2026-03-052026-06-08
News · 26 weeks28-100%
2025-12-142026-06-07
Mix1490d
- SEC Filings9(64%)
- Other4(29%)
- Offering1(7%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECSEC Form 10-Q filed by Inhibikase Therapeutics Inc.10-Q - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent ActivityWILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended March 31, 2026, and highlighted recent developments. "We were excited to enroll the first patient in our registrational IMPROVE-PAH study last month, and are very pleased with our early progress obtaining country regulatory approvals to support initiation of clinical sites, including being one of the first companies to successfully take advantage of the new European Medicines Agency FAST-EU (Facilitating and Acc
- SECSEC Form DEFA14A filed by Inhibikase Therapeutics Inc.DEFA14A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form DEF 14A filed by Inhibikase Therapeutics Inc.DEF 14A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form PRE 14A filed by Inhibikase Therapeutics Inc.PRE 14A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECInhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial HypertensionWILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), announced today that the first patient has been enrolled in the Company's pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). "Enrollment of the first patient in our IMPROVE-PAH trial is a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate th
- PRInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the "Inducement Plan"), effective as of March 31, 2026 (the "Effective Date"). The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The
- SECSEC Form S-8 filed by Inhibikase Therapeutics Inc.S-8 - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 10-K filed by Inhibikase Therapeutics Inc.10-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent ActivityWILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the year ended December 31, 2025 and highlighted recent developments. "The fourth quarter of 2025 was a transformational quarter for the Company as we transitioned to a global pivotal Phase 3 clinical study in Pulmonary Arterial Hypertension following receipt of a Written Response from a Type C interaction from the United States Food and Drug Administration," said Mark I
- ANALYSTLadenburg Thalmann initiated coverage on Inhibikase Therapeutics with a new price targetLadenburg Thalmann initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $4.00
- INSIDERDirector Aurentz Vincent returned 255,299 shares to the company, decreasing direct ownership by 33% to 510,596 units (SEC Form 4)4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERPresident & Head of R&D Cabell Christopher returned 338,282 shares to the company, decreasing direct ownership by 33% to 676,564 units (SEC Form 4)4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERDirector Munshi Amit returned 19,089 shares to the company, decreasing direct ownership by 33% to 38,176 units (SEC Form 4)4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- ANALYSTBofA Securities initiated coverage on Inhibikase Therapeutics with a new price targetBofA Securities initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $6.00
- INSIDERSEC Form 4 filed by Chief Executive Officer Iwicki Mark T4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 4 filed by President & Head of R&D Cabell Christopher4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Mcintyre David4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
IKT FAQ
7 questionsWhat does Inhibikase Therapeutics Inc. do?
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects...Where does IKT stock trade?
Inhibikase Therapeutics Inc. (IKT) is listed on NASDAQ.What sector and industry is IKT in?
Inhibikase Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Inhibikase Therapeutics Inc. go public?
Inhibikase Therapeutics Inc. (IKT) completed its IPO in 2020.What are analysts saying about IKT?
Inhibikase Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $400.00 price target on 2026-03-04. Recent price targets range from $400.00 to $1200.00.What companies are similar to IKT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IKT side-by-side with any of them on Quantisnow.How can I track IKT on Quantisnow?
Quantisnow aggregates Inhibikase Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IKT to receive live email and push alerts on every new disclosure.